Five Prime Therapeutics, Inc. (NASDAQ:FPRX) produced a 57.76% rally since recording the worst price of $25.97. Thanks to the latest 4.7% increase, it now trades at $40.97. Throughout the trading on Oct. 11, 2017, the share price floated between $39.11 and $41.36. This company shares are 40.2% off its target price of $57.44 and the current market capitalization stands at $1.19B. The recent change has given its price a 23.71% lead over SMA 50 and -32.81% deficit over its 52-week high. The stock witnessed 15.02% gains, 37.9% gains and 23.63% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found FPRX’s volatility during a week at 4.83% and during a month it has been found around 4.52%.Five Prime Therapeutics, Inc. (FPRX) Top Holders
Institutional investors currently hold around $956 million or 86.5% in FPRX stock. Look at its top three institutional owners. Fmr Llc owns $168.96 million in Five Prime Therapeutics, Inc., which represents roughly 14.2% of the company’s market cap and approximately 17.67% of the institutional ownership. Similar statistics are true for the second largest owner, Wellington Management Group Llp, which owns 2,923,140 shares of the stock are valued at $114.38 million. The third largest holder is Adage Capital Partners Gp, L.L.C., which currently holds $97.59 million worth of this stock and that ownership represents nearly 8.2% of its market capitalization.Five Prime Therapeutics, Inc. 13F Filings
At the end of June reporting period, 60 institutional holders increased their position in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by some 2,179,223 shares, 83 decreased positions by 2,204,154 and 23 held positions by 20,056,304. That puts total institutional holdings at 24,439,681 shares, according to SEC filings. The stock grabbed 10 new institutional investments totaling 388,619 shares while 43 institutional investors sold out their entire positions totaling 1,473,126 shares.Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Insider Trades
Multiple company employees have indulged in significant insider trading. Five Prime Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Ringo William R has sold 1,800 shares of Five Prime Therapeutics, Inc. (FPRX) in trading session dated Oct. 02, 2017. These shares are worth $72,468 and were traded at $40.26 each. The SEC filing shows that Ringo William R performed a sale of 2,000 shares. The Director disposed these shares by way of transaction on Sep. 28, 2017. The company’s shares were given away at $38 per share worth to an income of some $76,000 on account of Ringo William R.
Director, Ringo William R, sold 500 common shares of Five Prime Therapeutics, Inc. (FPRX) in the open market. In a transaction dated Mar. 01, 2017, the shares were put up for sale at an average price of $46.73, raking in a sum of $23,365.
In the transaction dated Feb. 01, 2017, the great number of shares disposed came courtesy the Director; Ringo William R disposed a total of 500 shares at an average price of $46.17, amounting to approximately $23,085.Five Prime Therapeutics, Inc. (FPRX) Analyst Guide
Several analysts have released their opinion on Five Prime Therapeutics, Inc. (NASDAQ:FPRX), with 5 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.